ALFA Finder| Revenue growth | 13.9% YoY |
|---|---|
| Margins | EBITDA margins improved 240 bps YoY to 15.0% |
| Demand visibility | Healthy demand environment in CDMO segment |
| Management confidence | High; confident in structural attractiveness of chosen geographies |
Growth
Revenue grew 13.9% YoY to Rs 1,167 Cr; EBITDA rose 35.4% YoY to Rs 175 Cr with margins improving to 15.0%.
Outlook
Acquisition of Oriflame India manufacturing for Rs 56 Cr; expect improved performance in branded formulations; CDMO capacity utilization improved to 50%.
Risks
API price volatility remains high in Q2; International and domestic branded segments showed muted performance this quarter.
Last quarter's promises, checked
Delivered
- Guided H1 FY27 double-digit volume growth → delivered 13.9% revenue growth (= BEAT)
- Guided API price bounce back in Q1 → delivered improved API prices noted in Q1 (= BEAT)
- Guided CDMO margin profile sustainability → delivered EBITDA margin improvement to 15% (= BEAT)
Partly delivered
- Guided API segment turnaround → delivered nearing EBITDA positivity but not yet achieved (= PARTIAL)
Missed
- Guided domestic branded growth above IPM → delivered 7.3% growth vs 13.9% group avg (= MISS)
Investor Presentation filed with BSE, NSE: AKUMS. Summary written with AI assistance from the document.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹768.80
- Market cap
- ₹12,100 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 33.3×Sector 43.8×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Earnings Call Transcript: Key Takeaways
Consolidated revenue ₹1,342 Cr (+31.9% YoY) and EBITDA ₹195 Cr (+106%), led by CDMO volumes. Management gave no numeric guidance. API still loss-making and domestic branded growth is only about 8%.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has fully utilized its IPO proceeds totaling Rs. 680 Crore as of September 30, 2026. Consequently, further monitoring agency reports are no longer required.
- Value
- ₹680.0 Cr
Akums Drugs & Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27: revenue INR 1,342 cr (+31.9% YoY), EBITDA INR 195 cr (14.5% margin), PAT INR 115 cr (+168.3% YoY). CDMO-led growth; API losses narrowing.
Akums Drugs & Pharmaceuticals Results Update
Akums reported Q2 FY27 revenue of ₹1,342 crore, up 31.9%, and PAT of ₹115 crore, up 168%. The release is a press update with highlights, not the full results statement.
Akums Drugs & Pharmaceuticals Q2 FY27 Results: Net Profit ₹114.6 Cr, Up 168.4% YoY
Akums Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹1,342 Cr (+31.9% YoY) and net profit of ₹114.6 Cr (+168.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹114.6 Cr · +168.4% YoY
Akums Drugs & Pharmaceuticals Management Change
Akums Drugs announced the resignation of Mr. Sunil Jaiswal, SVP R&D and Senior Management Personnel, effective 31 October 2026. The resignation was submitted on 5 August 2026 citing family commitments.